Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | AGER | Q15109 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6997223 | 0.89 | ADRB2 (0.51) | GRIN1GRIN2BPOLBKDM4EALDH1A1 | |
| SCHEMBL6993770 | 0.89 | KDM4E (0.60) | GRIN1GRIN2BKDM4EALDH1A1KCNH2 | |
| SCHEMBL6993777 | 0.89 | KDM4E (0.60) | GRIN1GRIN2BKDM4EALDH1A1KCNH2 | |
| SCHEMBL7032087 | 0.89 | KDM4E (0.60) | GRIN1GRIN2BKDM4EALDH1A1KCNH2 | |
| SCHEMBL7032100 | 0.89 | KDM4E (0.60) | GRIN1GRIN2BKDM4EALDH1A1KCNH2 | |
| SCHEMBL7034957 | 0.88 | KDM4E (0.46) | GRIN1GRIN2BPOLBKDM4EALDH1A1 | |
| SCHEMBL7025765 | 0.86 | KCNH2 (0.50) | POLBKDM4EALDH1A1KCNH2MEN1 | |
| SCHEMBL7035960 | 0.85 | KCNH2 (0.49) | POLBKDM4EALDH1A1KCNH2MEN1 | |
| SCHEMBL6622630 | 0.85 | MEN1 (0.53) | GRIN1GRIN2BPOLBKDM4EALDH1A1 | |
| SCHEMBL6619543 | 0.85 | MEN1 (0.53) | GRIN1GRIN2BPOLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| EP-1301510-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004446-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | GRIN1 456/4885GRIN2B 318/4885POLB 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.